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Abstract
Summary Low bone mineral density is frequently seen in
COPD patients. Advanced COPD, low BMI and muscle
depletion are risk factors for developing low bone mineral
density (BMD). Low bone mineral density is seen in 75%
of the GOLD stage IV patients.
Introduction We set out to investigate the prevalence of low
bone mineral density (BMD) in chronic obstructive
pulmonary disease (COPD) as well as the predictors of
abnormal bone mineral density.
Methods A cross-sectional design was used to evaluate 115
subjects with COPD (GOLD stages II–IV). Bone mineral
density (BMD) was measured using an ultrasound densi-
tometer. The forced expiratory volume in 1 s (FEV1) was
assessed and fat-free mass was measured using bioelectrical
impedance analysis. Chi-square tests and logistic regression
were used for analysis.
Results The prevalence of a T-score < −1.0 SD and > −2.5
SD was 28.6% in GOLD stage II, 40.3% in GOLD stage III
and 57.1% in GOLD stage IV. The prevalence of a T-score
≤−2.5 SD was 0% in GOLD stage II, 9.6% in GOLD stage
III and 17.9% in GOLD stage IV. In a logistic model FFM,
BMI and FEV1 were significant predictors of abnormal
bone mineral density. Patients in GOLD stage IV have a 7.6
times greater risk of abnormal bone mineral density than
patients in GOLD stage II.
Conclusions Low bone mineral density is frequently
present in COPD patients. Low FFM, BMI and FEV1 are
risk factors for developing a low T-score. A low FFM or
BMI in GOLD stage IV strongly suggests loss of BMD and
warrants further examination.
Keywords Chronic obstructive pulmonary disease .
Fat-free mass . Low bone mineral density . Lung function
Introduction
Patients with chronic obstructive pulmonary disease (COPD)
have a high risk of developing osteopenia and osteoporosis
[1, 2]. Osteopenia (T-score between −1.0 and −2.5) and
osteoporosis (T-score below −2.5) are conditions charac-
terized by a decrease in bone mass and density, causing
bones to become fragile. It is still not entirely clear which
mechanisms cause this problem [3]. Known risk factors for
developing osteoporosis in COPD are aging, female sex,
impaired nutritional status, low exercise levels, cortico-
steroids and tobacco smoking [4–6].
Nowadays, COPD is considered as a pulmonary disease
with many systemic manifestations. Patients with COPD
may have, in addition to a change in BMD, lowered fat-free
mass (FFM), muscle strength, endurance capacity, BMI and
heart failure. One explanation for these systemic effects is
the increase in systemic inflammation in COPD, which is
suggested by high levels of CRP, oxidative stress and other
(pro-) inflammatory mediators. The most important factor
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in this inflammatory process is tobacco smoke. Tobacco
smoke directly induces systemic damage, for instance, by
lowering the pH of bone tissue, resulting in absorption of
bone salts [7], but also has indirect systemic effects by
inducing an inflammatory response in the lungs with
production of systemic inflammatory mediators with effects
on bone and other organs [8]. Another explanation for the
low BMD in COPD is the low level of physical activity of
subjects with COPD. Patients with COPD experience
dyspnea during exertion, which may lead to inactivity with
negative effects on BMD [9].
In this study we examined the prevalence of a low bone
mineral density in COPD. Furthermore, the relationship of
BMD with lung function and two parameters which are
considered as parameters of systemic inflammation, namely
BMI and FFM, were studied.
Methods
Study design
A cross-sectional design was used to evaluate subsequent
subjects with COPD (GOLD stages II–IV) who were
referred for pulmonary rehabilitation to the Rehabilitation
Center of the University Medical Center Groningen.
Subjects were included if they had COPD GOLD stages
II–IV, were 40 years of age or older, and were in clinically
stable condition. Patients aged 80 and older were excluded
from this study.
Measurements
All subjects underwent a standardized measurement pro-
gram before the rehabilitation period in which lung
function, height and weight were taken and BMI was
calculated. The bioelectrical impedance, for calculation of
fat-free mass, was not measured in the first group of
patients, but only in the last 58 patients.
Bone mineral density measurement
We used quantitative ultrasound (QUS) for the assessment
of skeletal status. QUS is a peripheral bone densitometry
technique that is a useful screening technique, as it is
believed to provide not only an estimate of regional bone
mineral density (BMD), but also to evaluate bone quality
[10] and predict fractures risk [11]. Dual-energy X-ray
absorptiometry (DEXA) method is considered to be the
gold standard to measure bone mineral density (BMD), [12,
13], but research has shown that ultrasound densitometry is
a valid and reliable alternative for the DEXA method [14–
16]. QUS results correlate well with BMD measured by
DEXA at the heel [17]. Although calcaneal QUS devices
cannot formally diagnose osteoporosis, as they do not
actually measure BMD, they perform similarly to DEXA
when discriminating for patients with osteoporotic fracture
[18]. QUS has the advantage of not using ionizing
radiation. It is less expensive, more time-efficient and
easier to use than densitometry techniques.
In this study evaluation of skeletal status was based on
calcaneal QUS measurements, carried out by the SAHARA
Clinical Bone Sonometer (Hologic, Bedford, MA, USA).
Broadband ultrasound attenuation (BUA) and speed of
sound (SOS) were measured at a fixed region in the
calcaneus of the dominant foot. BUA and SOS were then
combined into a single parameter, the quantitative ultra-
sound index (QUI). An estimate of the heel BMD (eBMD)
was also derived. The estimated heel BMD is inferred from
a linear combination of BUA and SOS, and is not an actual
measurement of calcaneal BMD. T-scores for all subjects
were calculated on the basis of eBMD. T-score is defined as
the difference between the patient’s results and the mean
results obtained in a young population, expressed in units
of standard deviations (SD). Based on manufacturer-
derived T-scores for eBMD of the dominant heel, subjects
were classified into categories, i.e., greater than or equal
to −1 2SD, between −1 and −2.5 SD, and lower than or
equal to −2.5 SD.
Lung function
The forced expiratory volume in 1 s (FEV1) was measured
with the Masterscreen PFT (Jaeger, Hoechberg, Germany).
This computerized spirometer is reliable (r=0.84 to 0.96)
and valid, according to the American Thoracic Society
standards [19]. The FEV1% pred was used to determine the
level of COPD using the global initiative of obstructive
lung disease (GOLD) [20]. The GOLD classifies patients
into different stages based on FEV1% pred. Table 1 shows
the classification of COPD in GOLD stages.
Fat-free mass / fat-free mass index
Fat-free mass (FFM) and fat-free mass index (FFMI) were
measured using bioelectrical impedance analysis (Biostat
Table 1 Classification of COPD in GOLD stages
Stage
I: At risk FEV1≥80 % predicted
II: Mild COPD 50%≤FEV1<80 % predicted
III: Moderate COPD 30%≤FEV1< 50 % predicted
IV: Severe COPD FEV1<30 % predicted, or the presence of
respiratory failure*
*Respiratory failure: PaO2 < 8.0 kPa (60 mm Hg) with or without
PaCO2 > 6.7 kPa (50 mm Hg) while breathing air at sea level.
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1500, Bodystat Ltd., Douglas, Isle of Man, UK). Low fat-
free mass was defined as 15 kg/m2 or less for women and
16 kg/m2 or less for men [21]. Height and weight were
determined barefoot and body mass index (BMI=weight/
height2) was calculated. Low BMI was defined as
18.5 kg/m2 or less, based on WHO criteria.
Data analysis
The Statistical Package for Social Sciences (SPSS), version
12.0, was used to analyze the data. Results are presented as
means ± standard deviation. Differences in prevalence of T-
scores for the different GOLD stages, low/normal FFMI
and low/normal BMI were tested with the Chi-square test.
Logistic regression analysis was performed to determine
explaining variables of abnormal bone mineral density in
patients with COPD. Age, gender, FEV1, FFMI and BMI
were included as the covariates. We computed the odds
ratio (OR) and its 95% confidence intervals (CI). All p-
values < 0.05 were considered statistically significant.
Results
Participant characteristics
We evaluated 115 subjects with COPD (GOLD stages II–
IV). BMI was measured in 114 patients, fat-free mass index
(FFMI) in 58 patients. The characteristics of the patients are
shown in Table 2.
Figures 1, 2 and 3 shows the bone mineral density for
the different GOLD stages, low/normal BMI and low/
normal FFM.
Figure 1 shows that the prevalence of a low BMD
increases with a higher GOLD stage. The prevalence of T-
scores between −1 and −2.5 was 28.6% in GOLD stage II,
40.3% in GOLD stage III and 57.1% in GOLD stage IV.
Prevalence of T-scores lower than or equal to −2.5 was 0%
in GOLD stage II, 9.6% in GOLD stage III and 17.90% in
GOLD stage IV. There is a significant difference in bone
mineral density for the different GOLD stages (χ2=15.6,
df=4, p=0.004).
Figure 2 shows the prevalence of a low BMD for
underweight and normal-weight patients. Of the 114
patients, 104 had a normal BMI (> 18.5 kg/m2) and 10
had a low BMI (≤ 18.5 kg/m2). Of the underweight
patients, 20% had a normal BMD, 60% had a T-score
between −1 and −2.5 and 20% had a T-score lower than or
equal to −2.5. Of the patients with normal weight, 52.9%
had normal BMD, 39.4% a T-score between −1 and −2.5
and 7.7% had a T-score lower than or equal to −2.5.
Although it seems that the risk of a low bone mineral
density increased with low BMI, the difference in bone
mineral density for BMI is not significant (χ2= 4.9, df=2,
p>0.05).
Figure 3 shows the prevalence of low BMD for patients
with low and normal FFM. Of the 58 patients whose FFM
was measured, 20 patients had low FFM and 38 had normal
FFM. Of the 20 patients with low FFM, 20% had normal
BMD, 60% a T-score between −1 and −2.5 and 20% had a
T-score lower than or equal to −2.5. Of the 38 patients with
normal FFM, 55.3% had normal BMD, 34.2% a T-score
between −1 and −2.5 and 10.5% had a T-score lower than






























Fig. 1 Bone mineral density for the different GOLD stages
Table 2 Baseline
characteristics
BMI, body mass index; FFMI,
fat-free mass index, FEV1,
forced expiratory volume in
one second
Total group GOLD stage II GOLD stage III GOLD stage IV
Male/female (N) 62/53 18/17 26/26 18/10
Age (y) 60.0±10.8 59.3±12.4 61.6±10.2 57.9±9.6
Body composition
BMI (kg·m−2) 26.4±6.4 28.9±6.4 26.8±6.3 22.6±5.0
FFMI (kg·m−2) 17.3±3.4 18.6±3.5 17.4±3.6 16.3±2.9
BMD
T-score −0.90±1.18 −0.45±0.92 −0.89±1.15 −1.5±1.30
Pulmonary function
FEV1 (L) 1.26±0.59 1.90±0.53 1.12±0.32 0.74±0.22
FEV1 (% predicted) 43.4±16.9 64.7±8.9 39.8±6.0 23.6±4.6
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mineral density for FFM (χ2= 6.7, df=2, p=0.036). FFM
decreased with increasing severity of COPD and the risk of
low BMD increased with low FFM.
Predictors of abnormal bone mineral density
We also examined the predictors of abnormal bone mineral
density (T-score < −1.0) with logistic regression. In our
patients with COPD GOLD stages II–IV, FFM and BMI
were the most dominant predictors of low BMD. FEV1 was
found to be another relevant predictor of low BMD. Gender
and age were not significant predictors. Tables 3 and 4
shows the results of logistic regression.
To determine whether the prevalence of abnormal bone
mineral density was higher in patients with GOLD IV than
in GOLD II, logistic regression analyses were performed.
The results are shown in Table 4. When the results were
adjusted for age and gender, the risk of abnormal bone
mineral density was 7.6 times greater for patients with
GOLD IV than for patients with GOLD II (OR 7.6, 95% CI
2.4 to 24.3). The risk of abnormal bone mineral density was
4.9 times greater for patients with low FFM than for
patients with normal FFM. (OR 4.9, 95% CI 1.3 to 17.8).
The BMI also influence the risk of abnormal bone mineral
denisty, the risk is 4.7 times higher for patients with low
BMI than for patients with normal BMI (OR 4.7, 95 % CI
.96 to 23.7).
Discussion
The present study shows a high prevalence of low BMD in
COPD. This prevalence rises from 28.6% in GOLD stage II
to 75.0% in GOLD stage IV. Patients in GOLD IV have a
7.6 times greater risk of low BMD than patients with
GOLD II. In addition, a low FFM and, to a slightly less
extent, low BMI both increase the risk of low BMD.
Patients with low FFM have a 4.9 times greater risk of low
BMD than patients with a normal FFM. Low BMI increases
the risk of low BMD with 4.7 times. Logistic regression
showed that FFM, BMI and FEV1 are significant predictors
of abnormal bone mineral density (Table 5).
Our results are in line with previous studies. It has been
demonstrated that patients with advanced COPD are at risk
for having low fat-free mass [22]. Bolton et al. showed that
32% of the 81 COPD patients with an FEV1 of 16–105%
Table 3 Logistic regression model with covariates: age, gender, FEV1
and FFMI
B(SE) Exp (B) 95% CI
Constant 9.010(3.144)
Age −0.044(0.034) 0.957 0.896–1.02
Gender −0.954(0.682) 0.385 0.101–1.47
FFMI, kg/m2 −0.235 (0.107)* 0.791 0.642–.975
FEV1, l −1.290 (0.620)* 0.275 0.082–.927
Dependent is abnormal bone mineral density (T-score < −1 SD)


























Fig. 3 Bone mineral density for patients with low FFM (depleted)






























Fig. 2 Bone mineral density for underweight and normal-weight
patients
Table 4 Logistic regression model with covariates: age, gender, FEV1
and BMI
B(SE) Exp (B) 95%CI
Constant 3.294 (1.628)
Age 0.000(0.019) 1.000 0.964–1.039
Gender 0.414(0.434) 0.661 0.282–1.549
BMI, kg/m2 −0.081 (0.035)* 0.922 0.861–0.988
FEV1, l −0.800 (0.398)* 0.449 0.206–0.980
Dependent is abnormal bone mineral density (T-score < −1 SD)
R2 =0.12 (Cox & Snell), 0.16 (Nagelkerke)
*p<0.05
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pred. had osteoporosis, assessed by DEXA [23]. They did
not report a link between BMD and lung function, but
clearly showed that a low FFMI or BMI was associated
with increased protein catabolism and low BMD. Very
recently, Jørgensen showed that 68% of 62 COPD patients
with a mean FEV1 of 33%pred. had osteopenia or
osteoporosis, assessed by DEXA or spinal X-ray [2]. Our
research adds to these studies that both low lung function
and fat-free mass are associated with bone loss.
There may be several explanatory mechanisms for our
results. The first is the presence of systemic inflammation.
Among others, Gan et al. [24] found that reduced lung
function is associated with increased levels of systemic
inflammatory markers. In addition, systemic inflammation
is being recognized as a risk factor for osteoporosis,
cachexia and weight loss [24].
The second mechanism of reduced bone mass in COPD
is a low level of physical activity. Patients with COPD
experience dyspnea during exertion, which may lead to a
vicious circle of inactivity, deconditioning and increased
dyspnea on exertion. Recently, Pitta et al. [9] showed that
most patients with COPD spend less time walking and
standing and more time sitting and lying in daily life when
compared with sedentary healthy elderly subjects. It would
be compelling to study the effect on bone density of
interventions aiming at increasing daily physical activity. In
fact, it has already been shown that patients with COPD
present an improvement in bone mineral density after lung
volume reduction surgery, which has been ascribed to an
increase in physical activity [25].
The third mechanism is the corticosteroid-induced loss
of bone mass. In our study, the majority of patients were on
inhaled corticosteroids, especially in GOLD stage IV. Many
more patients with severe COPD had intermittent courses
of oral corticosteroids, but as we had no sufficient details
on previous corticosteroid medication, we were not able to
demonstrate a statistical effect of (inhaled) corticosteroid
dose on BMD.
Limitations of the study
We used the Sahara clinical bone sonometer to assess
skeletal status. Dual energy X-ray absorptiometry (DEXA)
is the most widely used and preferred quantitative tech-
nique for the assessment of skeletal status. Bone mineral
density measured by DEXA is the best predictor of fracture
risk and is currently considered the gold standard to
diagnose osteoporosis. The QUS can be used as a screening
technique, as it is believed to give an estimate of the BMD
and predict fracture risk [11]. Frost et al. showed that
DEXA and QUS were able to a similar extent to
discriminate the risk of fractures in postmenopausal women
[26].
Calcaneal QUS devices cannot formally diagnose oste-
oporosis, though, because they do not actually measure
BMD. The QUS test relies on an indirect measurement of
the anatomy (heel) to quantify the amount of bone loss in
other more direct areas of the body. The QUS can be
utilized as a screening test for osteoporosis, but up to 10%
of patients will get a “false normal” test result despite
having clinically significant osteoporosis [27]. QUS may
have a role in defining the COPD patients who should have
a DEXA scan.
Corticosteroid treatment diminishes bone mineral densi-
ty, especially in the vertebrae. We measured the bone
mineral density at the calcaneus. A scan of the calcaneus
may thus give an underestimation of the bone mineral
density in COPD patients using corticosteroids, suggesting
an even higher prevalence of low BMD.
Clinical implications
The results of our study show that patients with advanced
COPD (GOLD stage IV) are a risk group for developing
low BMD. In GOLD stage IV 75 % of the patients have a
low BMD. Because of the predicted worldwide increase in
COPD with subsequent bone problems such as fractures,
there should be an identification of COPD patients with a
high risk of osteoporosis. There recommend extra attention
for patients with advanced COPD, especially if they also
have low FFMI and/or low BMI.
In summary, this study shows that a low BMD is
frequently present in COPD. Advanced COPD, low BMI
and low FFM are risk factors for the presence of low BMD.
Abnormal bone mineral density is seen in 75% of the
GOLD stage IV patients. FFM, BMI and FEV1 are the most
important predictors of low BMD in COPD patients. Future
studies are needed to determine the best way to identify
high-risk patients and whether early treatments such as
lifestyle interventions or medication are able to reverse the
osteoporotic process.
Table 5 Three different logistic regression models for abnormal
BMD in COPD patients
N Adjusted OR (95 % CI)
GOLD II 35 1.0
GOLD III 52 2.4 (0.97 to 6.1) *
GOLD IV 28 7.6 (2.4 to 24.3) *
Normal FFM 38 1.0
Low FFM 20 4.9 (1.3 to 17.8) *
Normal BMI 104 1.0
Low BMI 10 4.7 (0.96 to 23.7) *
Results are adjusted for age and gender
*p<0.05
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